ATHE ALTERITY THERAPEUTICS LTD

Nasdaq alteritytherapeutics.com


$ 4.59 $ 0.05 (1.1 %)    

Friday, 24-Oct-2025 12:01:21 EDT
QQQ $ 617.15 $ 1.15 (0.19 %)
DIA $ 472.20 $ 2.36 (0.5 %)
SPY $ 677.18 $ 0.74 (0.11 %)
TLT $ 91.46 $ -0.10 (-0.11 %)
GLD $ 377.82 $ -0.75 (-0.2 %)
$ 4.6
$ 4.52
$ 4.59 x 1
$ 4.69 x 92
$ 4.52 - $ 4.60
$ 1.00 - $ 7.00
26,144
na
402.13M
$ 0.99
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 alterity-therapeutics-presents-data-from-ath434-201-randomized-double-blind-phase-2-clinical-trial-in-msa-at-2025-international-congress-of-parkinsons-disease-and-mds

– Data demonstrate ATH434 slows disease progression and stabilizes orthostatic hypotension –– New analysis increases overall co...

 alterity-to-present-multiple-system-atrophy-drug-trial-results-at-major-parkinsons-conference-in-hawaii

Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated...

 alterity-therapeutics-phase-2-trial-shows-ath434-slowed-progression-of-rare-brain-disorder-msa

Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated...

 alterity-therapeutics-raises-20m-to-advance-fda-path-for-promising-neurodegenerative-drug

Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated...

 alterity-faces-asx-scrutiny-over-timing-of-market-sensitive-mri-study-announcement

Alterity Therapeutics Limited (‘ATH'): ASX Aware LetterASX refers to the following:A.ATH's announcement titled ‘Alterit...

 alterity-therapeutics-announces-topline-data-from-ath434-202-open-label-phase-2-clinical-trial-in-individuals-with-multiple-system-atrophy

– ATH434 Demonstrated Clinical Benefit on the Unified MSA Rating Scale and Global Measures of Neurological Symptoms –– Neuroima...

 alterity-therapeutics-says-peer-reviewed-publication-in-annals-of-clinical-and-translational-neurology-highlights-use-of-msa-atrophy-index-developed-to-diagnose-and-track-disease-progression-in-multiple-system-atrophy

Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated...

 why-levi-strauss-shares-are-trading-higher-by-8-here-are-20-stocks-moving-premarket

Levi Strauss & Co. (NYSE: LEVI) stock rose as Q2 results beat expectations and full-year guidance was raised. Other gainers...

 alterity-ceo-to-share-updates-on-msa-drug-at-investor-fireside-chat

Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION